BCMA-CAR-T CELLS

The present invention is directed to a monoclonal anti-human BCMA antibody, or a single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 6 and VL having the amino acid sequence of SEQ ID NO: 7. The present invention is also directed to a BCMA chimeric antigen receptor (CAR) comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. The monoclonal antibody of the present invention exhibits selective and high-affinity binding to BCMA. BCMA CAR-T cells based on BCMA scFv of the present invention significantly decreases multiple myeloma tumor growth in an animal model..

Medienart:

Patent

Erscheinungsjahr:

2019

Erschienen:

2019

Enthalten in:

Europäisches Patentamt - (2019) vom: 10. Okt. Zur Gesamtaufnahme - year:2019

Sprache:

Englisch

Beteiligte Personen:

WU LIJUN [VerfasserIn]
GOLUBOVSKAYA VITA [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
C07K: Peptides (peptides containing β-lactam rings c07d; (...)
che

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2019-10-10, Last update posted on www.tib.eu: 2024-04-01, Last updated: 2024-04-09

Patentnummer:

CA3095864

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA00305456X